We want to thank everybody who came to visit our booth at this year’s ASHP Midyear Clinical Meeting & Exhibition. We always appreciate the opportunity to show off our products to the people who need them most.
At ConsortiEX, we work diligently to create solutions designed specifically for the unique needs of health system pharmacies. The result is our Assure-Trak® IV Workflow Management Dynamic Patient Specific Compounding application a dynamically configurable IV Workflow solution to enhance patient safety and optimize[...]
Just last week, ConsortiEX proudly announced our new InsightRX Passive Audit Monitoring module.
Understanding the rules and regulations behind DSCSA Compliance can be a daunting task. As deadlines pass, the FDA regularly updates what it means to be compliant. ConsortiEX is proud to offer DSCSA Compliance as a Service (CaaS). Our CaaS module removes the burden of being compliant from the dispenser community with[...]
Today, cost and quality issues surrounding compounded sterile preparations (CSP’s) have nearly every major health system investigating what it takes to re-insource production. Most are looking at a hub and spoke approach, where their central-fill Batch Compounding can support the CSP production needs of all the[...]
ConsortiEX is proudly attending ASHP Midyear. Stop by Booth 900 to see how our intuitive Pharmacy-Focused ERP solutions can enhance your patient safety, ensure quality control, and simplify compliance, first-hand and in-person. Our new InsightRX Passive Audit Monitoring hood will be on display.
Introducing InsightRX Passive Audit Monitoring: See what others miss.
Several key industry players have issued responses to the FDA in regard to the recent draft guidance on the use of Product Identifiers, and the policy on grandfathered product, in compliance with the Drug Supply Chain Security Act (DSCSA).
On Sep. 9, 2018, the FDA released a Final Guidance regarding the use of product identifiers on packages and homogenous cases of product as mentioned in the Drug Supply Chain Security Act (DSCSA).
The practice of compounding medicines can provide important public health opportunities. The FDA’s compounding program – including implementation of the compounding provisions of the law – is a priority for the agency. We recognize that in delivering on implementation commitments, we must balance the need to preserve[...]